Workflow
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
内克塔内克塔(US:NKTR) ZACKS·2025-08-09 00:46

Key Takeaways Nektar's Q2 loss of 2.95pershareandrevenuesbeatestimates.Revenuesfellafterthe2024saleoftheHuntsvillefacility,endingproductrevenuestreams.PhaseIIbtrialsonrezpegforatopicdermatitisandalopeciaareataaremovingforward.NektarTherapeutics (NKTR)reportedalossof2.95 per share and revenues beat estimates.Revenues fell after the 2024 sale of the Huntsville facility, ending product revenue streams.Phase IIb trials on rezpeg for atopic dermatitis and alopecia areata are moving forward.Nektar Therapeutics (NKTR) reported a loss of 2.95 per share for the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 3.13.Intheyear−agoquarter,thecompanyhadreportedalossof3.13. In the year-ago quarter, the company had reported a loss of 3.76 per share.Excluding the impact ...